Associate Professor Liz Caldon
Associate Professor Liz Caldon runs a basic and translational research program on estrogen receptor positive (ER+) breast cancer, basal-like breast cancers and ovarian cancers. She is Head of the Replication and Genome Stability Group at the Garvan Institute of Medical Research. Her group has built models of hormone therapy and CDK4-6 inhibitor resistance to understand the evolution of ER+ breast cancers as they become refractory to standard of care therapies. Specific interests of her group are the understanding of tumour cell evolution through single cell modelling, cell cycle-based therapies, therapy repurposing, and the development of targeted approaches in therapy resistant disease. Liz is a Cancer Institute NSW Fellow, and a recipient of the Mavis Robertson fellowship from the NBCF. She is an Associate Editor for the journals Oncogenesis and Endocrine Oncology.
- 2002Connaught Graduate Fellowship - University of Toronto
- 2003LH Ainsworth Scholarship in Cancer Research
- 2004Beth Yarrow Scholarship
- 2005Cancer Institute NSW Scholar
- 2010Young Garvan Fellowship
- 2011Cure Cancer Australia Postdoctoral Fellowship
- 2011National Breast Cancer Foundation Postdoctoral Fellowship
- 2013“Best Translational Research Presentation” - Lowy Cancer Symposium - UNSW - Sydney - Australia
- 2013Cure Cancer Conference and Professional Development Grant
- 2014Cancer Institute Career Development Fellowship
- 2015CHAMP Private Equity Young Pioneer Award
- 2017Heliflite Young Explorer Award
- 2017National Breast Cancer Foundation Career Development Fellowship
- 2018The Ridley Ken Davies Award
- 2021Cancer Institute NSW Fellowship
- 2021Mavis Robertson NBCF Fellowship
- 2022The journal of pathology. Clinical research10.1002/cjp2.269
High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
- 2021NPJ breast cancer10.1038/s41523-021-00312-x
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Cyclin E2 Promotes Whole Genome Doubling in Breast Cancer.
- 2020Breast cancer research : BCR10.1186/s13058-020-01318-2
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
- Endocrine-related cancer10.1530/ERC-19-0501
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.